In this review:
- Impact of physical activity in patients with IBD
- Four-year follow-up of “top-down” therapy for Crohn’s disease
- Switching from IV to SC infliximab in patients with IBD
- Safety and efficacy of ustekinumab in paediatric ulcerative colitis
- Safety and efficacy of ustekinumab in paediatric Crohn’s disease
- Ustekinumab dose escalation in paediatric Crohn’s disease
- Guselkumab for perianal fistulising Crohn’s disease
- Co-antibody therapy in refractory Crohn’s disease
- Co-antibody therapy in refractory ulcerative colitis
- Mediterranean diet in patients with early Crohn’s disease
- GLP-1 receptor agonists in ulcerative colitis and Crohn’s disease
- Intestinal ultrasound and fecal calprotectin predict recurrence after ileocecal resection
- Upadacitinib in perianal Crohn’s disease
Please login below to download this issue (PDF)